Situation Report

SCIENCE By Kai Kupferschmidt                                                                       March 11, 2015

Researchers in Sierra Leone today started a new phase II trial of an experimental drug in Ebola patients. The first participant received an injection of the therapeutic, called TKM-Ebola, this morning at an Ebola treatment unit in Kerry Town. The trial may expand to other sites; the study team hopes to have an answer fast so that it can either move on to another drug or start a phase III study of TKM-Ebola.

Produced by Tekmira Pharmaceuticals in Burnaby, Canada, TKM-Ebola is made of synthetic, small interfering RNAs packaged into lipid nanoparticles. The RNAs target three of Ebola’s seven genes, blocking the virus’s replication. TKM-Ebola has been shown to work well in monkeys; the efficacy trial in humans is only starting now because there was not enough of the drug available earlier. Also, the RNAs have been adapted to the strain circulating at the moment.

The study does not have a placebo arm; all patients at the trial site are eligible for the drug, and researchers hope to determine whether it works by comparing them with patients treated elsewhere.

REUTERS     by Tom Miles                                                                                        March 11, 2015

GENEVA -Waning interest in Ebola could jeopardize efforts to stamp out the world's worst recorded outbreak of the disease, the World Health Organization said on Wednesday.

Case numbers have fallen to a low level and it should be possible to stop transmission by mid-year, but the disease is "not waning" and it is much too early to assume the outbreak will end, said WHO Assistant Director General Bruce Aylward.

"We talk often about how steep the drop in cases has been. The only thing that has dropped more quickly and more steeply is the new contributions in financing," he told reporters in Geneva. 

...the failure to make further inroads is "alarming", Aylward said.

"Getting from here to zero is going to require another reinvestment (in the drive to tackle the outbreak)."

WHO PRESS RELEASE                                                March 10, 2015

The WHO Director-General has commissioned a panel of outside independent experts to undertake an assessment on all aspects of WHO’s response in the Ebola outbreak. This is in response to a resolution passed during the Ebola Special Session of the Executive Board in January 2015.

Dame Barbara Stocking will chair the panel. She was formerly Chief Executive of Oxfam GB (2001-13) and during this time led major humanitarian responses. Currently she is President of Murray Edwards College, University of Cambridge, UK.

The other panel members are: Professor Jean-Jacques Muyembe-Tamfun, Director-General of the National Institute for Biomedical Research, Democratic Republic of the Congo; Dr Faisal Shuaib, Head of the National Ebola Emergency Operations Center, Nigeria; Dr Carmencita Alberto-Banatin, independent consultant and advisor on health emergencies and disasters, Philippines; Professor Julio Frenk, Dean of the Faculty, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA; and Professor Ilona Kickbusch, Director of the Global Health Programme at the Graduate Institute of International and Development Studies, Geneva, Switzerland.

The panel will present a first progress report on its work to the 68th World Health Assembly in May 2015.

THE ECONOMIST                                                                                                   March 9, 2015

As in all Ebola episodes, preventing infection in West Africa during what has been the worst outbreak in history has placed a lot of effort on looking after those dealing with the victims. New high-tech equipment is now available for use by health care workers, but in some countries it may be inappropriate....

Health care workers inside a USAID-funded Ebola clinic in Liberia wearing protective gear. Some of the best protective gear or technology is not available to African countries because of high costs or other conditions.  Photos by Abbas Dulleh • Associated Press,